Prognostic value of ctDNA-derived maximum somatic allele frequency in patients with metastatic gastric cancer

Key Points

Baseline maximum somatic allele frequency correlates with outcomes in metastatic gastric cancer.
A notable increase in maximum somatic allele frequency was linked to worse prognostic implications with survival.
Assessment of baseline maximum somatic allele frequency serves as a method for enhanced risk stratification in clinical practice.
Incorporating this biomarker may improve personalized treatment approaches, yet external validation is necessary.

Abstract

Baseline MSAF is an independent prognostic biomarker in metastatic GC and may reflect underlying biological aggressiveness. Incorporating MSAF into risk stratification frameworks could enhance prognostic classification and inform personalized treatment strategies.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Kim et al. (Thu,) studied this question.

synapsesocial.com/papers/69a75abfc6e9836116a20fb8 https://doi.org/https://doi.org/10.1177/17588359251414103

Bookmark

View Full Paper